INSM Insmed Incorporated

Q2 2025 10-Q

Filed: Aug 7, 2025Period ending Jun 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Insmed Incorporated (INSM) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 7, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Risk Factors

• No material changes in risk factors since 10-K filed February 20, 2025
• Continued risk from clinical trial uncertainties impacting regulatory approval timelines

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$107M

▲ +18.9% YoY▲ +15.7% QoQ

Net Income

-$322M

▼ -7.0% YoY▼ -25.4% QoQ

Net Margin

-299.5%

▲ +3327bp YoY▼ -2306bp QoQ

Source: XBRL data from Insmed Incorporated Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Insmed Incorporated Quarterly Reports

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Insmed Incorporated

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.